Lam Research Corporation is the world's preeminent supplier of etch and deposition equipment for semiconductor wafer fabrication, holding the #1 or #2 global position in every major category it competes in. Lam's product portfolio spans plasma etch systems (Flex, Kiyo, Syndion, Versys), CVD/ALD deposition platforms (ALTUS, VECTOR, Striker), electrochemical deposition (SABRE for copper damascene), UV thermal processing (SOLA), and wafer cleaning (Da Vinci, EOS, SP series). The company is one of the three dominant wafer fab equipment (WFE) suppliers globally alongside Applied Materials and Tokyo Electron.
Lam's installed base of roughly 80,000 systems in the field generates a growing Customer Support Business Group (CSBG) revenue stream — encompassing spares, upgrades, and refurbishment — that provides annuity-like cash flows independent of equipment order cycles. CSBG was approximately 35–40% of FY2025 revenue, dampening cyclicality and supporting margin floors.
Customers include Samsung, SK Hynix, Micron, TSMC, Intel, and virtually every major memory and logic chipmaker. NAND flash is Lam's largest end-market by WFE share — making NAND capex cycles the primary earnings swing factor. China represents a historically significant revenue source (~20–30%), currently subject to evolving US export controls. Fiscal year ends in late June.
Investment Thesis
Lam Research is levered to two of the most powerful structural demand drivers in semiconductors: the NAND capex recovery cycle and the AI-driven build-out of HBM and advanced packaging. After a severe NAND down-cycle in FY2024 ($14.9B revenue), FY2025 rebounded strongly to $18.4B (+23.7% YoY) and consensus projects continued acceleration through FY2027E ($30.6B avg). CEO Tim Archer at the May 2026 Bernstein conference cited AI demand as creating a "$140 billion WFE market boom."
Bull drivers: Gate-all-around transistor transitions (TSMC N2, Samsung SF2) require new atomic-layer deposition steps where Lam's Striker platform is a critical enabling tool. HBM4 capacity expansion for AI accelerators demands new etch and deposition steps per stack layer — Lam's sweet spot. NAND 3D layer count creep (now 300+ layers at leaders) structurally increases etch steps per die. CSBG recurring revenue provides a ~$6–7B floor regardless of system cycle. Morgan Stanley upgraded to Overweight in May 2026.
Key risks: At 82x TTM P/E and 66.9x EV/EBITDA, the stock prices in a steep earnings recovery that is not yet in reported results. China export-control risk remains acute — any BIS rulemaking affecting 14nm-and-above equipment would hit Lam directly. The quarterly avg price target of $338.92 is essentially at current levels, suggesting the market has already priced the base case recovery. The 10:1 stock split (October 2025) did not change fundamentals but has broadened the retail investor base.
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $14.63B | $17.23B | $17.43B | $14.91B | $18.44B |
| Revenue Growth | +45.5% | +17.8% | +1.2% | -14.5% | +23.7% |
| COGS | $7.82B | $9.36B | $9.65B | $7.85B | $9.46B |
| Gross Profit | $6.81B | $7.87B | $7.78B | $7.05B | $8.98B |
| Gross Margin | 46.5% | 45.7% | 44.6% | 47.3% | 48.7% |
| R&D Expense | $1.49B | $1.60B | $1.73B | $1.90B | $2.10B |
| SG&A Expense | $0.83B | $0.89B | $0.83B | $0.87B | $0.98B |
| Operating Income | $4.48B | $5.38B | $5.17B | $4.26B | $5.90B |
| Operating Margin | 30.6% | 31.2% | 29.7% | 28.6% | 32.0% |
| EBITDA | $4.89B | $5.71B | $5.64B | $4.91B | $6.34B |
| Net Income | $3.91B | $4.61B | $4.51B | $3.83B | $5.36B |
| EPS (Diluted, post-split) | $2.69 | $3.27 | $3.32 | $2.90 | $4.15 |
| Shares Outstanding (Diluted) | 1,453M | 1,406M | 1,358M | 1,320M | 1,290M |
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Cash & ST Investments | $5.73B | $3.66B | $5.37B | $5.85B | $6.39B |
| Total Assets | $15.89B | $17.20B | $18.78B | $18.74B | $21.35B |
| Total Debt | $4.99B | $5.01B | $5.01B | $4.98B | $4.76B |
| Net Debt / (Net Cash) | $0.58B | $1.48B | -$0.33B | -$0.86B | -$1.63B |
| Total Liabilities | $9.86B | $10.92B | $10.57B | $10.21B | $11.48B |
| Stockholders' Equity | $6.03B | $6.28B | $8.21B | $8.54B | $9.86B |
| Book Value / Share (post-split) | $4.15 | $4.47 | $6.05 | $6.47 | $7.89 |
| Current Ratio | 3.30x | 2.69x | 3.16x | 2.97x | 2.21x |
| Goodwill & Intangibles | $1.62B | $1.62B | $1.79B | $1.77B | $1.81B |
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $3.59B | $3.10B | $5.18B | $4.65B | $6.17B |
| Capital Expenditures | -$0.35B | -$0.55B | -$0.50B | -$0.40B | -$0.76B |
| Free Cash Flow | $3.24B | $2.55B | $4.68B | $4.26B | $5.41B |
| FCF Margin | 22.1% | 14.8% | 26.8% | 28.6% | 29.4% |
| Dividends Paid | -$0.73B | -$0.82B | -$0.91B | -$1.02B | -$1.15B |
| Share Buybacks | -$2.70B | -$3.87B | -$2.02B | -$2.84B | -$3.42B |
| Stock-Based Compensation | $0.22B | $0.26B | $0.29B | $0.29B | $0.34B |
| Net Debt Issuance | -$0.86B | -$0.01B | -$0.02B | -$0.26B | -$0.51B |
| Multiple | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 (Current Price) |
|---|---|---|---|---|---|
| P/E Ratio | 23.8x | 13.7x | 18.6x | 36.4x | 82.0x |
| P/S Ratio | 6.35x | 3.65x | 4.82x | 9.35x | 23.1x |
| P/B Ratio | 15.4x | 10.0x | 10.2x | 16.3x | 43.2x |
| P/FCF Ratio | 28.7x | 24.6x | 18.0x | 32.8x | 78.6x |
| EV/EBITDA | 19.1x | 11.3x | 14.8x | 28.2x | 66.9x |
| EV/Sales | 6.39x | 3.74x | 4.80x | 9.29x | 23.0x |
| FCF Yield | 3.49% | 4.06% | 5.57% | 3.05% | 1.27% |
| Dividend Yield | 0.78% | 1.30% | 1.08% | 0.73% | 0.30% |
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Return on Equity | 64.8% | 73.4% | 54.9% | 44.8% | 54.3% |
| Return on Assets | 24.6% | 26.8% | 24.0% | 20.4% | 25.1% |
| ROIC | 32.4% | 37.8% | 31.3% | 25.1% | 34.0% |
| Return on Capital Employed | 36.2% | 42.6% | 35.5% | 29.6% | 39.9% |
| Asset Turnover | 0.92x | 1.00x | 0.93x | 0.80x | 0.86x |
| Current Ratio | 3.30x | 2.69x | 3.16x | 2.97x | 2.21x |
| Inventory Turnover | 2.91x | 2.36x | 2.00x | 1.86x | 2.20x |
| Days Sales Outstanding | 75.5 | 91.4 | 59.1 | 61.7 | 66.9 |
| Interest Coverage | 21.5x | 29.1x | 27.8x | 23.0x | 33.1x |
| Metric | FY2025A | FY2027E | FY2028E | FY2029E | FY2030E |
|---|---|---|---|---|---|
| Revenue (Avg) | $18.44B | $30.62B | $35.54B | $37.74B | $50.59B |
| EBITDA (Avg) | $6.34B | $10.18B | $11.82B | $12.55B | $16.82B |
| EPS (Avg, post-split) | $4.15 | $7.97 | $9.64 | $10.31 | $12.68 |
| EPS Growth | +43.1% | +92.0% | +21.0% | +7.0% | +23.0% |
| # Analysts (Rev) | — | 25 | 22 | 11 | 19 |
| Fwd P/E (at $340.31) | 82.0x | 42.7x | 35.3x | 33.0x | 26.8x |
Lam executed a 10-for-1 stock split in October 2025, increasing shares outstanding from ~130M (pre-split) to ~1.25–1.29B post-split. The split was cosmetic — no change to market cap or fundamentals. Share count shown above is on post-split basis for all years. Lam has repurchased approximately $14.9B in shares over the past five years (FY2021–FY2025), reducing diluted share count from 1,453M to 1,290M (-11.2%). The quarterly dividend of $1.01/share (post-split, annualized ~$4.04/share) represents a 1.19% yield at the current price and has grown at a ~10% CAGR.
| Name | Title | Type | Shares | Price | Date |
|---|---|---|---|---|---|
| Fernandes Neil J | Senior Vice President | Sale | 7,659 | $309.60 | Jun 1, 2026 |
| Fernandes Neil J | Senior Vice President | Sale | 18,170 | $255.14 | May 1, 2026 |
| Harter Ava | Chief Legal Officer | Exercise + Sale | 6,010 | $258.66 | Apr 27, 2026 |
| Bettinger Douglas R | CFO & EVP | Exercise + Sale | 50,057 | $224.03 | Mar 4, 2026 |
| Talwalkar Abhijit Y | Director | Gift | 4,571 | — | Mar 10, 2026 |
NAND capex recovery exceeds consensus. The NAND market is in early-innings recovery as AI-driven storage demand (inference model caches, data lakes) and PC/mobile replacement cycles absorb inventory overhangs. Samsung and SK Hynix have telegraphed capex increases for 2026. Each 300+ layer NAND device requires ~10+ etch steps where Lam's Flex and Kiyo platforms are the industry standard. A stronger-than-expected NAND recovery could push FY2027E revenue above the $30.6B consensus toward $32–34B, driving EPS toward $9–10 and compressing the forward multiple toward 35x — still premium, but defensible.
HBM and advanced packaging are structural, not cyclical. HBM4 for NVIDIA B-series GPUs and AMD Instinct MI400 requires new through-silicon-via etch and deposition processes where Lam holds commanding share. AI training and inference server demand is projected to grow 40-50% annually through 2028, making HBM a secular growth vector independent of PC/NAND cycles. Lam's Syndion TSV system is designed specifically for these stacks.
Gate-all-around deepens moat. GAA transistors (TSMC N2, Samsung SF2) require 3–5x more ALD steps than FinFET per layer. Lam's Striker ALD platform is a critical enabling technology. This is a multi-year structural tailwind that begins ramping now and extends through the decade.
Capital returns are exceptional. At $5.41B FCF, Lam returned $4.57B to shareholders in FY2025 and still grew cash on the balance sheet. With $1.63B net cash and debt declining, buyback capacity remains substantial.
Valuation has re-rated dramatically ahead of earnings recovery. The stock has risen from $83 to $340 in 12 months — a 4x move — while FY2025 EPS of $4.15 actually declined from FY2022's $3.27 on a compounded basis. At 82x TTM P/E and 66.9x EV/EBITDA, Lam trades at all-time valuation highs on reported results. The quarterly consensus price target of $338.92 implies the stock is already at fair value. Any miss versus aggressive forward expectations, particularly in NAND order timing, could trigger a 30-40% correction.
China export controls are a structural, not temporary, headwind. China has historically represented 25–35% of Lam's system revenue. BIS rules already restrict certain advanced etch tools for sub-14nm applications in China. Further rulemaking — which both US parties support — could expand restrictions to older nodes, eliminating a meaningful revenue stream permanently. Lam cannot fully replace lost China revenue from other geographies in the near term.
WFE cyclicality is severe and consensus timing may slip. FY2024 was a 14.5% revenue decline year; if the NAND capex recovery is delayed 2–4 quarters, FY2026 could disappoint versus optimistic consensus. Memory customers including Micron and Samsung have histories of abrupt capex reversals when oversupply signals emerge. One major NAND capex pause would ripple through Lam's order book disproportionately.
Customer concentration amplifies risk. Samsung, SK Hynix, and Micron together likely account for over 50% of Lam revenue. A strategic shift by any one of these three customers — whether toward domestic equipment suppliers (NAURA, AMEC), or equipment pause — creates an outsized quarterly revenue swing that the market punishes severely given the 1.82 beta.
US BIS restrictions on advanced etch and deposition equipment exports to China are already in effect for sub-14nm processes. Lam's China exposure (~20–30% of historical revenue) is more vulnerable than AMAT because etch tools are more directly implicated in the restricted node transition. Any escalation — covering NAND stacking equipment for mature nodes — would be an immediate revenue shock with limited near-term offset.
Lam is the most NAND-exposed of the big-3 WFE suppliers. NAND capex is inherently lumpy — driven by pricing, inventory cycles, and bit demand growth — and can swing ±30-50% year over year. A NAND oversupply signal in late 2026 or 2027 could trigger rapid customer capex cuts, compressing Lam's revenue well below consensus expectations and driving multiple compression simultaneously (double bear scenario).
At 82x TTM P/E and 66.9x EV/EBITDA, Lam's stock is priced for near-perfect execution of a NAND/HBM supercycle through 2028. This leaves zero margin of safety. At a 1.82 beta, any broad semiconductor sector derating, Fed rate shock, or AI capex deceleration story would hit Lam first and hardest. The quarterly avg analyst PT of $338.92 essentially matches the current price, leaving no buffer.
Samsung Electronics alone may represent 25%+ of Lam's system revenue in NAND-intensive periods. SK Hynix (HBM leader) and Micron are the other anchors. Each customer's capex cycle can shift Lam's quarterly revenue by hundreds of millions of dollars. Samsung's domestic equipment preference and ongoing investment in NAURA-sourced tools for certain mature-node applications creates a longer-term substitution risk in the China-restricted market.
The October 2025 10:1 stock split lowered the nominal price from ~$900 to ~$90, broadening the retail investor base. Combined with a +300% run in 12 months and heavy momentum-fund positioning, the stock is susceptible to sharp reversals on any negative catalyst. Beta of 1.82 vs. SOX is already elevated; momentum positioning amplifies downside tail risk asymmetrically.
Tokyo Electron (TEL) is Lam's primary direct competitor in etch (Tactras, Certas) and deposition (Probus). AMAT competes in CVD/ALD deposition. Chinese domestic equipment makers (NAURA, Advanced Micro-Fabrication Equipment/AMEC) are advancing rapidly at mature nodes, potentially capturing share in the China market if export controls create forced substitution demand. Longer term, any TEL breakthrough in advanced etch at leading nodes would threaten Lam's incumbent advantage.
WFE supercycle above consensus. NAND recovery exceeds expectations with Samsung and SK Hynix deploying +20% capex vs. plan. HBM4 ramp for AI accelerators drives outsized deposition/etch demand. FY2027E EPS beats to $10–11 vs. consensus $7.97. Market assigns 44–48x forward P/E as investors price in FY2028 EPS of ~$11–12. EV/EBITDA normalizes toward 35–40x on FY2027 EBITDA of ~$11B+ = enterprise value of ~$400–440B = equity ~$480. Morgan Stanley Overweight upgraded May 2026 reflects this scenario.
Consensus recovery on schedule. Revenue tracks analyst consensus at $30.6B in FY2027E with EPS of ~$7.97. Market re-rates to ~42–43x FY2027E P/E as earnings catch up to the current multiple, leaving the stock essentially flat from here over 12 months. EV/EBITDA compresses from 67x toward 40x on forward EBITDA of ~$10.2B = EV ~$410B = equity ~$342. Consistent with last-quarter avg PT of $338.92. The stock does the work through earnings growth, not multiple expansion.
NAND capex pause + export control escalation. NAND oversupply signals in late 2026 force Samsung/Micron capex cuts; FY2027E EPS misses to $5–6 vs. $7.97 consensus. China BIS rules expand to cover additional etch categories, removing a further 5–10% of revenue. Multiple contracts to 30–35x forward earnings on $5.50 EPS = $165–193 price range, say ~$180. EV/EBITDA on depressed EBITDA of ~$6–7B at 27–30x = similar range. The 1.82 beta and momentum positioning make the downside swift rather than gradual — a repeat of FY2022–2024 cycle trough.
This report was generated using FMP financial data as of June 3, 2026. All per-share figures use the post-10:1 split basis (October 2025). For informational purposes only — does not constitute investment advice. Past performance is not indicative of future results.